Close

Antibody Off-target Identification and Specificity Profiling Service Using Membrane Proteome Array Technology

The human genome contains ∼21,000 distinct protein-coding genes, out of which ∼5,360 code for membrane proteins. Membrane proteins are critical for many cellular processes, such as signaling transduction, ion transportation, pathogen interaction, and 60% of drugs currently in the market target membrane proteins. The antibody off-target identification and specificity profiling service is the leading solution for antibody and CAR-T specificity profiling using membrane proteome array technology. This cell-based array contains more than 6000 human membrane proteins assembled to determine the specificity of antibodies, CAR-T cell therapies, and other biotherapeutics. By testing antibodies or chimeric antigen receptor (CAR) T cells against an array of native proteins, you know exactly what specificity you are getting.

High Throughput Membrane Protein Array Screening Services

Antibody Off-target Identification and Specificity Profiling Service
using the membrane protein library, flow cytometry, and unfixed cells for detection.

High Throughput Membrane Protein Array Screening Services 2

Antibody Off-target Identification and Specificity Profiling Service
making your projects successful.

High Throughput Membrane Protein Array Screening Services 3

Antibody Off-target Identification and Specificity Profiling Service

With years of experience in membrane proteins production, Creative Biolabs is dedicated to offering antibody off-target identification and specificity profiling service to determine the specificity of antibodies, CAR-T cell therapies, and other biotherapeutics using membrane proteome array technology. Our strategies of antibody off-target identification and specificity profiling service include 3 main steps: 1) optimize conditions for detecting antibody binding; 2) high throughput screening; 3) confirm all identified targets in a second flow cytometry titration experiment. Please contact us for more detailed information to know how we can help.

High Throughput Membrane Protein Array Screening Services workflow. Fig.1 Antibody Off-target Identification and Specificity Profiling Service Workflow. (Gerhart, 2020)

Antibody Off-target Identification and Specificity Profiling Application

The screening service was validated by testing the specificity of antibodies with known membrane protein targets. The antibody against an ion channel (anti-P2X3) was tested. The known target for each anti-P2X3 antibody was readily identified. The service also identified binding to an additional membrane protein, informing the final lead selection in this program to avoid off-target binding that could cause patient side effects.

Assess specificity and off-target binding of antibodies. Fig.2 Assess specificity and off-target binding of antibodies. (Huston-Paterson, 2016)

High throughput membrane proteome array screening identified off-target CAR-T cells. More than 6000 membrane proteins were expressed in HEK293T and QT6 cells and then screened with soluble Fc-tagged proteins to assess binding.

Specificity identification and off-target binding of CAR-T. Fig.3 Specificity identification and off-target binding of CAR-T. (Lee, 2020)

The systematic array of the membrane proteome in live human cells provides a unique opportunity to test the function of each membrane protein in live cell-based assays, such as the identification of novel receptors for Zika and Ebola viruses.

High Throughput Membrane Protein Array Screening for pathogen receptor discovery. Fig.4 High throughput membrane proteome array screening for pathogen receptor discovery. (Huston-Paterson, 2016)

Frequently Asked Questions

Q: What does the array contain?
A: Antibody off-target identification and specificity profiling service contains more than 6000 human membrane proteins natively expressed in human cells.

Q: What's cells expressed membrane proteins?
A: Membrane proteins were expressed in unfixed human cells including HEK293 cells and Avian QT6 cells.

Q: What are the deliverables that I will receive?
A: You will receive a detailed report containing the binding profiles of your antibodies/ligands/CAR-T and validation results on identified targets.

References

  1. Tan, Y.; et al. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. Blood Cancer J. 2021, 11(4):71.
  2. Gerhart, J.; et al. Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage. PLoS ONE, 2020, 15(7):e0234792.
  3. Huston-Paterson, D.J.; et al. Screening the Membrane Protein: A High-Throughput Platform for Identifying Membrane Protein Antibody Targets. Genetic engineering & biotechnology news. 2016, 36(15):18-19.
  4. Lee, J.; et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. The Journal of clinical investigation. 2020, 130(12):6317-6324.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us